VolitionRx Ltd. plans to offer and sell its common shares in an underwritten public offering.
The life sciences company plans to grant underwriters an overallotment option to buy additional shares.
Net proceeds will be used for continued product development, clinical studies, product commercialization, working capital and other general corporate purposes.
Oppenheimer & Co. Inc. is acting as the sole book-running manager for the proposed offering. National Securities Corp. is acting as a co-manager for the offering.
